BC Platforms, a world leader in providing powerful genomic data management and analysis solutions, today announced the appointment of Karen Tay Koh to its Board. Singapore-based Karen, who has extensive experience and networks in finance, healthcare and education, will work closely with the company’s recently established Singapore-based entity to support the Company’s activities in the Asia Pacific region, including China.
BC Platforms’ Asia strategy includes a strong precision medicine focus both in healthcare delivery, as well as in genomics-related research. Genomics is becoming a mainstream solution for improved clinical decision-making. In parallel, BC Platforms’ goal is to provide the genomic IT infrastructure to build cohort studies, representing Asia’s rich multi-ethnicity that is of interest from a medical perspective. To this end, partnering with key institutions in the local ecosystem across the region is essential in establishing world-leading genomic data management and interpretation infrastructure.
Karen Tay Koh has long been driven to positively impact human healthcare, from managing hospitals, to setting up medical schools, and advising on healthcare deals. She has served as a C-level executive and Board Director in both private and public companies and organisations in the US, Denmark and Asia. She has deep expertise in executing business-building entrepreneurial initiatives across companies in various stages in their life cycle, from start-ups to dominant industry incumbents.
Karen commented: “It’s fascinating to see how the future of healthcare is racing towards precision medicine. To make that future a reality, where people can benefit daily from the advances genomics brings, will require significant access and operational expertise to deliver seamless services. Together with BC Platforms, and its pioneering analytics platform supporting more effective clinical decision-making, we relish the opportunity to help transform clinical practice in healthcare.”
Tero Silvola, CEO of BC Platforms commented: “We are delighted to welcome Karen to the team. Her impressive diversity of board experience, and breadth of operational experience, plus her extensive local relationships will be a tremendous asset in supporting our Asian efforts in the rapidly growing precision medicine market.”